Business
Sanara MedTech Inc. Reports Unaudited Preliminary Financial Results for the Fourth Quarter and Full Year 2025; Introduces Full Year 2026 Financial Guidance
FORT WORTH, TX, Jan. 23, 2026 (GLOBE NEWSWIRE) -- Sanara MedTech Inc. (“Sanara MedTech,” “Sanara,” the “Company,” “we,” “our” or “us”) (Nasdaq: SMTI), a medical technology company focused on developing and commercializing transformative technologies to improve clinical outcomes and reduce healthcare expenditures in the surgical market, today reported certain unaudited preliminary financial results for the fourth quarter and full year ended December 31, 2025, and introduced its financial guidance
About this update from Sanara Medtech Inc.
[{"type":"image","alt":"Sanara MedTech Inc.","displaySize":"","headline":null,"caption":"Sanara MedTech Inc.","className":"","disableSlideshowImg":false,"size":{"original":{"width":300,"height":101,"url":"https://media.zenfs.com/en/globenewswire.com/3143d8c56f18cb5802cdd7512b027911"},"resized":{"url":"https://s.yimg.com/ny/api/res/1.2/Ep49t7MgFH9O.p4QWc4Ouw--/YXBwaWQ9aGlnaGxhbmRlcjt3PTQyMDtoPTE0MTtjZj13ZWJw/https://media.zenfs.com/en/globenewswire.com/3143d8c56f18cb5802cdd7512b027911","width":300,"height":101}},"lazy":false},{"type":"text","content":"FORT WORTH, TX, Jan. 23, 2026 (GLOBE NEWSWIRE) -- Sanara MedTech Inc. (“Sanara MedTech,” “Sanara,” the “Company,” “we,” “our” or “us”) (Nasdaq: SMTI), a medical technology company focused on developing and commercializing transformative technologies to improve clinical outcomes and reduce healthcare expenditures in the surgical market, today reported certain unaudited preliminary financial results for the fourth quarter and full year ended December 31, 2025, and introduced its financial guidance for the full year ending December 31, 2026.","length":544,"tagName":"p"},{"type":"text","content":"Selected Fourth Quarter and Full Year 2025 Preliminary Financial Results (Unaudited):","length":85,"tagName":"p"},{"type":"list","items":[{"val":[{"type":"text","content":"Net revenue for the fourth quarter of 2025 is expected to be in the range of $27.2 million to $27.7 million, an increase of approximately 3% to 5%, compared to $26.3 million in the fourth quarter of 2024.","length":214,"tagName":"p"},{"type":"list","items":[{"val":[{"type":"text","content":"As previously disclosed, the Company experienced growth in sales of BIASURGE® Advanced Surgical Solution (“BIASURGE”) in the fourth quarter of 2024, as a result of supply chain issues and shortages of intravenous fluids and saline solutions experienced by the broader industry due to Hurricane Helene. Excluding approximately $1.8 million of BIASURGE sales in the fourth quarter of 2024, net revenue in the fourth quarter of 2025 is expected to increase approximately 11% to 13% year-over-year.(1)","length":497,"tagName":"p"}]}],"tagName":"ul","bulletedList":true,"length":497,"olType":false}]},{"val":[{"type":"text","content":"Net revenue for the full year 2025 is expected to be in the range of $102.7 million to $103.2 million, an increase of approximately 19%,...